Madagascar

Population 2017
26 million

Tuberculosis profile

Estimates of TB burden*, 2017

<table>
<thead>
<tr>
<th>Category</th>
<th>Number (thousands)</th>
<th>Rate (per 100,000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>13 (7.8–20)</td>
<td>52 (31–79)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.65 (0.29–1.1)</td>
<td>2.5 (1.1–4.5)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>61 (39–87)</td>
<td>238 (154–340)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.5 (0.69–2.7)</td>
<td>6 (2.7–11)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.44 (0.087–1.1)</td>
<td>1.7 (0.34–4.2)</td>
</tr>
</tbody>
</table>

Estimated TB burden by age and sex (thousands)*, 2017

- 0-14 years
- > 14 years
- Total

<table>
<thead>
<tr>
<th>Sex</th>
<th>Number</th>
<th>Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>3.7 (1.5–6)</td>
<td>23 (11–36)</td>
</tr>
<tr>
<td>Males</td>
<td>4.1 (1.6–6.6)</td>
<td>38 (17–58)</td>
</tr>
<tr>
<td>Total</td>
<td>7.9 (4.4–11)</td>
<td>61 (39–87)</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- Total cases notified: 31,783
- New and relapse: 31,370
- % tested with rapid diagnostics at time of diagnosis: 50%
- % with known HIV status: 80%
- % bacteriologically confirmed among pulmonary: 87%

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2017: 52% (36–80)
- TB patients facing catastrophic total costs: 0.24 (0.12–0.39)

TB/HIV care in new and relapse TB patients, 2017

- Patients with known HIV-status who are HIV-positive: 156 <1%
- % on antiretroviral therapy: 45%

Drug-resistant TB care, 2017

- New cases: 250 (13–490)
- Previously treated cases: 612
- Total number: 862

Estimated MDR/RR-TB cases among notified pulmonary TB cases: 17

Laboratory-confirmed cases

- MDR/RR-TB: 30, XDR-TB: 0

Patients started on treatment

- MDR/RR-TB: 18, XDR-TB: 0

Treatment success rate and cohort size

<table>
<thead>
<tr>
<th>Year</th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>2016</td>
<td>84%</td>
<td>27,818</td>
</tr>
<tr>
<td>2016</td>
<td>79%</td>
<td>2,120</td>
</tr>
<tr>
<td>2015</td>
<td>57%</td>
<td>7</td>
</tr>
<tr>
<td>2015</td>
<td>57%</td>
<td>7</td>
</tr>
</tbody>
</table>

TB preventive treatment, 2017

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 9%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 23% (21–25)

TB financing, 2018

- National TB budget (US$ millions): 2.7
- Funding source: domestic, 122% international, <1% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-02-09

Data: www.who.int/tb/data